Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors

Lizza E. L. Hendriks*, Clemence Henon, Edouard Auclin, Laura Mezquita, Roberto Ferrara, Clarisse Audigier-Valette, Julien Mazieres, Corentin Lefebvre, Audrey Rabeau, Sylvestre Le Moulec, Sophie Cousin, Boris Duchemann, Cecile le Pechoux, Angela Botticella, Samy Ammari, Anas Gazzah, Caroline Caramella, Julien Adam, Emmanuele Lechapt, David PlanchardDirk De Ruysscher, Anne-Marie Dingemans, Benjamin Besse

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1244-1254
Number of pages11
JournalJournal of Thoracic Oncology
Volume14
Issue number7
DOIs
Publication statusPublished - Jul 2019

Keywords

  • NSCLC
  • Checkpoint inhibition
  • Brain metastases
  • survival
  • Disease specific Graded Prognostic Assessment
  • PATIENTS PTS
  • OPEN-LABEL
  • NIVOLUMAB
  • PEMBROLIZUMAB
  • DOCETAXEL
  • SYSTEM
  • EFFICACY
  • LIFE

Cite this

Hendriks, L. E. L., Henon, C., Auclin, E., Mezquita, L., Ferrara, R., Audigier-Valette, C., Mazieres, J., Lefebvre, C., Rabeau, A., Le Moulec, S., Cousin, S., Duchemann, B., le Pechoux, C., Botticella, A., Ammari, S., Gazzah, A., Caramella, C., Adam, J., Lechapt, E., ... Besse, B. (2019). Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors. Journal of Thoracic Oncology, 14(7), 1244-1254. https://doi.org/10.1016/j.jtho.2019.02.009